UA77441C2 - 4,5-dihydro-1h-pyrazole derivatives as potent cb1 receptor antagonists, methods for their preparation (variants), intermediate, pharmaceutical composition and method for its preparation - Google Patents

4,5-dihydro-1h-pyrazole derivatives as potent cb1 receptor antagonists, methods for their preparation (variants), intermediate, pharmaceutical composition and method for its preparation Download PDF

Info

Publication number: UA77441C2
Authority: UA; Ukraine
Prior art keywords: group; formula; phenyl; dihydro; compound
Prior art date: 2001-09-21

Application number

UA20040402981A

Other languages

English (en)

Ukrainian (uk)

Inventor

Cornelis G Kruse

Arnoldus H J Herremans

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2002-09-17

Publication date

2006-12-15

2002-09-17 Application filed filed Critical

2006-12-15 Publication of UA77441C2 publication Critical patent/UA77441C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 13
238000002360 preparation method Methods 0.000 title claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
230000003389 potentiating effect Effects 0.000 title abstract description 4
239000002464 receptor antagonist Substances 0.000 title abstract description 4
229940044551 receptor antagonist Drugs 0.000 title abstract description 4
MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical class C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 73
229930003827 cannabinoid Natural products 0.000 claims abstract description 13
239000003557 cannabinoid Substances 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 6
125000000217 alkyl group Chemical group 0.000 claims description 32
238000006243 chemical reaction Methods 0.000 claims description 25
-1 trifluoromethoxy, nitro, amino Chemical group 0.000 claims description 24
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
125000000468 ketone group Chemical group 0.000 claims description 18
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 16
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
125000005842 heteroatom Chemical group 0.000 claims description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
125000003342 alkenyl group Chemical group 0.000 claims description 11
125000003277 amino group Chemical group 0.000 claims description 10
125000004663 dialkyl amino group Chemical group 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 9
239000003960 organic solvent Substances 0.000 claims description 9
125000003545 alkoxy group Chemical group 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000000623 heterocyclic group Chemical group 0.000 claims description 8
125000002950 monocyclic group Chemical group 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
125000002619 bicyclic group Chemical group 0.000 claims description 6
125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
208000035475 disorder Diseases 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
125000001544 thienyl group Chemical group 0.000 claims description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 4
125000004429 atom Chemical group 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
230000005062 synaptic transmission Effects 0.000 claims description 4
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
MYLBTCQBKAKUTJ-UHFFFAOYSA-N 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine Chemical compound C1=CN=CC2=C(SC)C(C)=C(SC)N21 MYLBTCQBKAKUTJ-UHFFFAOYSA-N 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
208000027559 Appetite disease Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
208000016192 Demyelinating disease Diseases 0.000 claims description 2
206010012305 Demyelination Diseases 0.000 claims description 2
206010012735 Diarrhoea Diseases 0.000 claims description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
208000014094 Dystonic disease Diseases 0.000 claims description 2
206010014612 Encephalitis viral Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000010412 Glaucoma Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
206010066364 Hypersexuality Diseases 0.000 claims description 2
229930194542 Keto Natural products 0.000 claims description 2
208000026139 Memory disease Diseases 0.000 claims description 2
206010028813 Nausea Diseases 0.000 claims description 2
206010028980 Neoplasm Diseases 0.000 claims description 2
208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
208000018737 Parkinson disease Diseases 0.000 claims description 2
208000028017 Psychotic disease Diseases 0.000 claims description 2
206010040070 Septic Shock Diseases 0.000 claims description 2
208000007107 Stomach Ulcer Diseases 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
208000000323 Tourette Syndrome Diseases 0.000 claims description 2
208000016620 Tourette disease Diseases 0.000 claims description 2
206010044565 Tremor Diseases 0.000 claims description 2
206010047700 Vomiting Diseases 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
125000004103 aminoalkyl group Chemical group 0.000 claims description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
125000002393 azetidinyl group Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
230000002490 cerebral effect Effects 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 2
206010013663 drug dependence Diseases 0.000 claims description 2
208000010118 dystonia Diseases 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
201000005917 gastric ulcer Diseases 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
230000002140 halogenating effect Effects 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000004404 heteroalkyl group Chemical group 0.000 claims description 2
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000008693 nausea Effects 0.000 claims description 2
208000004296 neuralgia Diseases 0.000 claims description 2
208000021722 neuropathic pain Diseases 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
208000023504 respiratory system disease Diseases 0.000 claims description 2
230000036303 septic shock Effects 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 2
125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 2
201000002498 viral encephalitis Diseases 0.000 claims description 2
230000008673 vomiting Effects 0.000 claims description 2
125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 1
241000212977 Andira Species 0.000 claims 1
101100287724 Caenorhabditis elegans shk-1 gene Proteins 0.000 claims 1
241000282326 Felis catus Species 0.000 claims 1
208000018522 Gastrointestinal disease Diseases 0.000 claims 1
235000010469 Glycine max Nutrition 0.000 claims 1
244000068988 Glycine max Species 0.000 claims 1
206010019196 Head injury Diseases 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
241001083878 Licania tomentosa Species 0.000 claims 1
208000008238 Muscle Spasticity Diseases 0.000 claims 1
208000012902 Nervous system disease Diseases 0.000 claims 1
208000025966 Neurological disease Diseases 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
208000010877 cognitive disease Diseases 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
230000006735 deficit Effects 0.000 claims 1
208000010643 digestive system disease Diseases 0.000 claims 1
208000018685 gastrointestinal system disease Diseases 0.000 claims 1
125000006413 ring segment Chemical group 0.000 claims 1
230000035939 shock Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
238000002844 melting Methods 0.000 description 66
230000008018 melting Effects 0.000 description 66
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 47
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
150000004702 methyl esters Chemical class 0.000 description 15
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 14
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 13
239000002253 acid Substances 0.000 description 13
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
102000018208 Cannabinoid Receptor Human genes 0.000 description 12
108050007331 Cannabinoid receptor Proteins 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000005557 antagonist Substances 0.000 description 10
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 9
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
238000004949 mass spectrometry Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000003756 stirring Methods 0.000 description 7
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
239000012071 phase Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
230000005526 G1 to G0 transition Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
229940065144 cannabinoids Drugs 0.000 description 4
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
PPVUWDCETZMPLT-UHFFFAOYSA-N 1,3-dihydropyrazole-2-carboxamide Chemical compound NC(=O)N1CC=CN1 PPVUWDCETZMPLT-UHFFFAOYSA-N 0.000 description 3
SKLKZKAMWPQZLM-UHFFFAOYSA-N 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C1=NNCC1C1=CC=CC=C1 SKLKZKAMWPQZLM-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
206010029216 Nervousness Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
OJGMBLNIHDZDGS-UHFFFAOYSA-N N-ethyl-N-phenylamine Natural products CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000003217 pyrazoles Chemical class 0.000 description 2
238000011160 research Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241000722948 Apocynum cannabinum Species 0.000 description 1
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
241000159610 Roya <green alga> Species 0.000 description 1
FNVCLGWRMXTDSM-WOJBJXKFSA-N Samidin Chemical compound C1=CC(=O)OC2=C3[C@@H](OC(=O)C)[C@@H](OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-WOJBJXKFSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
235000005607 chanvre indien Nutrition 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
150000001907 coumarones Chemical class 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
240000004308 marijuana Species 0.000 description 1
230000015654 memory Effects 0.000 description 1
150000002730 mercury Chemical class 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
XGPBRZDOJDLKOT-UHFFFAOYSA-N praeruptorin A Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)=CC)C(C)(C)O1 XGPBRZDOJDLKOT-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
FNVCLGWRMXTDSM-UHFFFAOYSA-N samidin Natural products C1=CC(=O)OC2=C3C(OC(=O)C)C(OC(=O)C=C(C)C)C(C)(C)OC3=CC=C21 FNVCLGWRMXTDSM-UHFFFAOYSA-N 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
BUXTXUBQAKIQKS-UHFFFAOYSA-N sulfuryl diisocyanate Chemical compound O=C=NS(=O)(=O)N=C=O BUXTXUBQAKIQKS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Hematology (AREA)
Oncology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Virology (AREA)
Addiction (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)

UA20040402981A 2001-09-21 2002-09-17 4,5-dihydro-1h-pyrazole derivatives as potent cb1 receptor antagonists, methods for their preparation (variants), intermediate, pharmaceutical composition and method for its preparation UA77441C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01203849		2001-09-21
PCT/EP2002/010435 WO2003026648A1 (en)	2001-09-21	2002-09-17	4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity

Publications (1)

Publication Number	Publication Date
UA77441C2 true UA77441C2 (en)	2006-12-15

Family

ID=8181042

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040402981A UA77441C2 (en)	2001-09-21	2002-09-17	4,5-dihydro-1h-pyrazole derivatives as potent cb1 receptor antagonists, methods for their preparation (variants), intermediate, pharmaceutical composition and method for its preparation

Country Status (20)

Country	Link
US (2)	US6974810B2 (pl)
EP (1)	EP1429762A1 (pl)
JP (1)	JP4313672B2 (pl)
KR (1)	KR100950430B1 (pl)
CN (2)	CN1529595A (pl)
AR (1)	AR036598A1 (pl)
AU (1)	AU2002333853B2 (pl)
BR (1)	BR0208253A (pl)
CA (1)	CA2442245C (pl)
HR (1)	HRP20030913A2 (pl)
HU (1)	HUP0402113A3 (pl)
IL (2)	IL157704A0 (pl)
MX (1)	MXPA03009439A (pl)
NO (1)	NO20041170L (pl)
NZ (1)	NZ528280A (pl)
PL (1)	PL367814A1 (pl)
RU (1)	RU2286988C2 (pl)
UA (1)	UA77441C2 (pl)
WO (1)	WO2003026648A1 (pl)
ZA (1)	ZA200307218B (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100950430B1 (ko) *	2001-09-21	2010-04-02	솔베이 파마슈티칼스 비. 브이	효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en)	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20050239859A2 (en) *	2003-09-03	2005-10-27	Solvay Pharmaceuticals Gmbh	Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
JP2007521322A (ja) *	2003-09-18	2007-08-02	メルク　エンド　カムパニー　インコーポレーテッド	置換スルホンアミド類
BRPI0415851A (pt) *	2003-10-24	2007-01-02	Solvay Pharm Gmbh	utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos
AR046132A1 (es) *	2003-10-24	2005-11-23	Solvay Pharm Gmbh	Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
US20050143441A1 (en) *	2003-10-27	2005-06-30	Jochen Antel	Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) *	2003-10-27	2005-06-09	Jochen Antel	Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
TW200522944A (en)	2003-12-23	2005-07-16	Lilly Co Eli	CB1 modulator compounds
EP1713475B1 (en) *	2004-01-30	2008-07-30	Solvay Pharmaceuticals B.V.	1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
TW200602314A (en)	2004-05-28	2006-01-16	Tanabe Seiyaku Co	A novel pyrrolidine compound and a process for preparing the same
CA2586011C (en)	2004-07-12	2011-07-19	Cadila Healthcare Limited	Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
RU2007119315A (ru) *	2004-10-25	2008-11-27	Зольвай Фармасьютиклз Гмбх (De)	Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний
US7700597B2 (en)	2004-12-03	2010-04-20	Schering Corporation	Substituted piperazines as CB1 antagonists
CA2613678A1 (en)	2005-06-02	2006-12-07	Glenmark Pharmaceuticals S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
AU2006264649A1 (en)	2005-06-30	2007-01-11	Prosidion Limited	GPCR agonists
EP1743890A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
RU2008109911A (ru) *	2005-08-17	2009-09-27	Зольвай Фармасьютикалз Гмбх (De)	Способ применения соединений, ингибирующих калиевые каналы
WO2007084450A2 (en) *	2006-01-18	2007-07-26	Schering Corporation	Cannibinoid receptor modulators
EP2023920B1 (en) *	2006-05-05	2012-06-13	Jenrin Discovery	Cannabinoid receptor antagonists/inverse agonists
US7964728B2 (en)	2006-07-06	2011-06-21	Solvay Pharmaceuticals B.V.	Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
SA07280510B1 (ar) *	2006-09-22	2012-02-07	سولفاي فارماسوتيكالز بي . في	سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5
CA2666587C (en) *	2006-10-20	2015-12-22	Solvay Pharmaceuticals B.V.	Micellar nanoparticles of chemical substances
US7923026B2 (en)	2006-10-20	2011-04-12	Solvay Pharmaceuticals B.V.	Embedded micellar nanoparticles
EA016507B1 (ru)	2007-01-04	2012-05-30	Прозидион Лимитед	Пиперидиновые агонисты gpcr
CL2008000018A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
EP2114933B1 (en)	2007-01-04	2011-09-07	Prosidion Ltd	Piperidine gpcr agonists
PE20081849A1 (es)	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
WO2008130616A2 (en) *	2007-04-19	2008-10-30	Schering Corporation	Diaryl morpholines as cb1 modulators
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN101318931B (zh) *	2007-06-04	2010-05-19	上海阳帆医药科技有限公司	二芳基取代吡唑衍生物、其制备方法和用途
KR20100020998A (ko) *	2007-06-15	2010-02-23	솔베이 파마슈티칼스 비. 브이	칸나비노이드 ｃｂ1 수용체 조절제로서의 4,5-디하이드로-(1ｈ)-피라졸 유도체
US8410135B2 (en) *	2007-06-15	2013-04-02	Solvay Pharmaceuticals B.V.	4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
WO2009005646A2 (en) *	2007-06-28	2009-01-08	Schering Corporation	Substituted piperazines as cb1 antagonists
CN101790521A (zh) *	2007-06-28	2010-07-28	英特维特国际股份有限公司	作为cb1拮抗剂的取代哌嗪
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
US7655685B2 (en) *	2007-11-02	2010-02-02	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
PL2963031T3 (pl)	2007-11-30	2019-08-30	Zynerba Pharmaceuticals, Inc.	Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
AR070898A1 (es) *	2008-03-18	2010-05-12	Solvay Pharm Bv	Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AR071995A1 (es) *	2008-06-16	2010-07-28	Solvay Pharm Bv	Derivados de 3,4-diaril-4,5-dihidro-1h-pirazol-1-carboxamidina sustituidos con fluor que tienen actividad antagonista cb1, procesos de preparacion y composiciones farmaceuticas que los contienen
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
AR072539A1 (es) *	2008-08-01	2010-09-01	Solvay Pharm Bv	Sintesis de derivados de 3,4-diaril -4,5-dihidro -(1h) - pirazol -1- carboxamida
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8217038B2 (en)	2009-10-07	2012-07-10	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
AR079935A1 (es)	2010-01-29	2012-02-29	Abbott Healthcare Products Bv	Sintesis de derivados de pirazolin carboxamidina sustituida
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012068529A2 (en)	2010-11-18	2012-05-24	Jenrin Discovery	Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
CN103459383B (zh)	2011-09-30	2016-06-22	财团法人国家卫生研究院	吡唑类化合物
US8680131B2 (en)	2012-07-25	2014-03-25	Jenrin Discovery, Inc.	Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP2919779B1 (en)	2012-11-13	2021-01-06	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Cannabinoid receptor mediating compounds
US11155521B2 (en)	2012-11-13	2021-10-26	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Cannabinoid receptor mediating compounds
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
WO2015172059A1 (en) *	2014-05-09	2015-11-12	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Pyrazole derivatives and their use as cannabinoid receptor mediators
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2022128050A1 (en)	2020-12-14	2022-06-23	Symrise Ag	Medicament for fighting inflammation and pain
US20250263367A1 (en) *	2021-05-17	2025-08-21	The United States of America, as represented by the Secretary, Department of Health and Human Serice	A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives
US20250026723A1 (en) *	2021-12-10	2025-01-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human	Cannabinoid Receptor Modulating Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL158178B (nl) *	1974-07-12	1978-10-16	Philips Nv	Werkwijze ter bereiding van insekticide preparaten die een pyrazolinederivaat bevatten, aldus verkregen gevormde preparaten, en werkwijze ter bereiding van pyrazolinederivaten met insekticide werking.
JPH03173887A (ja) *	1989-03-27	1991-07-29	Nissan Chem Ind Ltd	スルタムスルホンアミド及び除草剤
FR2692575B1 (fr) *	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
PL208098B1 (pl) *	2000-03-23	2011-03-31	Solvay Pharm Bv	Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposób wytwarzania związków oraz ich zastosowanie
KR100950430B1 (ko) *	2001-09-21	2010-04-02	솔베이 파마슈티칼스 비. 브이	효력있는 ｃｂ1-길항 작용을 가지는4,5-디하이드로-1ｈ-피라졸 유도체
US20050143441A1 (en) *	2003-10-27	2005-06-30	Jochen Antel	Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) *	2003-10-27	2005-06-09	Jochen Antel	Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds

2002
- 2002-09-17 KR KR1020047004076A patent/KR100950430B1/ko not_active Expired - Fee Related
- 2002-09-17 BR BR0208253-5A patent/BR0208253A/pt not_active IP Right Cessation
- 2002-09-17 CN CNA02808134XA patent/CN1529595A/zh active Pending
- 2002-09-17 RU RU2003130268/04A patent/RU2286988C2/ru not_active IP Right Cessation
- 2002-09-17 IL IL15770402A patent/IL157704A0/xx unknown
- 2002-09-17 WO PCT/EP2002/010435 patent/WO2003026648A1/en not_active Ceased
- 2002-09-17 CA CA2442245A patent/CA2442245C/en not_active Expired - Fee Related
- 2002-09-17 HR HR20030913A patent/HRP20030913A2/hr not_active Application Discontinuation
- 2002-09-17 US US10/472,529 patent/US6974810B2/en not_active Expired - Fee Related
- 2002-09-17 HU HU0402113A patent/HUP0402113A3/hu unknown
- 2002-09-17 PL PL02367814A patent/PL367814A1/pl not_active Application Discontinuation
- 2002-09-17 JP JP2003530285A patent/JP4313672B2/ja not_active Expired - Fee Related
- 2002-09-17 NZ NZ528280A patent/NZ528280A/en not_active IP Right Cessation
- 2002-09-17 UA UA20040402981A patent/UA77441C2/uk unknown
- 2002-09-17 AU AU2002333853A patent/AU2002333853B2/en not_active Ceased
- 2002-09-17 CN CNA2007101543471A patent/CN101195604A/zh active Pending
- 2002-09-17 EP EP20020799409 patent/EP1429762A1/en not_active Withdrawn
- 2002-09-17 MX MXPA03009439A patent/MXPA03009439A/es active IP Right Grant
- 2002-09-18 AR ARP020103508A patent/AR036598A1/es unknown
2003
- 2003-09-02 IL IL157704A patent/IL157704A/en not_active IP Right Cessation
- 2003-09-15 ZA ZA200307218A patent/ZA200307218B/en unknown
2004
- 2004-03-19 NO NO20041170A patent/NO20041170L/no not_active Application Discontinuation
2005
- 2005-11-03 US US11/265,090 patent/US7608718B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0208253A (pt)	2004-04-13
CN101195604A (zh)	2008-06-11
RU2003130268A (ru)	2005-01-27
AR036598A1 (es)	2004-09-22
CN1529595A (zh)	2004-09-15
US20070259884A1 (en)	2007-11-08
CA2442245A1 (en)	2003-04-03
KR100950430B1 (ko)	2010-04-02
PL367814A1 (pl)	2005-03-07
US7608718B2 (en)	2009-10-27
JP2005503428A (ja)	2005-02-03
ZA200307218B (en)	2005-03-16
IL157704A0 (en)	2004-03-28
AU2002333853B2 (en)	2006-07-13
KR20040035845A (ko)	2004-04-29
RU2286988C2 (ru)	2006-11-10
MXPA03009439A (es)	2004-02-12
EP1429762A1 (en)	2004-06-23
HRP20030913A2 (en)	2004-06-30
WO2003026648A1 (en)	2003-04-03
JP4313672B2 (ja)	2009-08-12
HUP0402113A3 (en)	2012-05-29
US6974810B2 (en)	2005-12-13
US20040106800A1 (en)	2004-06-03
CA2442245C (en)	2010-03-30
NO20041170L (no)	2004-06-21
NZ528280A (en)	2005-11-25
HUP0402113A2 (hu)	2005-01-28
IL157704A (en)	2008-07-08

Publication	Publication Date	Title
US6974810B2 (en)	2005-12-13	4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
AU2002333853A1 (en)	2003-06-26	4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
EP1560580B1 (en)	2011-01-12	Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors
EP1658272B1 (en)	2007-07-25	Novel gamma-secretase inhibitors
UA74066C2 (en)	2005-10-17	Derivatives of 4,5-dihydro-1n-pyrazole with antagonistic activity relative to receptors of canabis-1, a method for the preparation trhereof, a pharmaceutical composition and a method for treatment
HRP20040085A2 (en)	2004-08-31	Novel 4,5-dihydro-1h-pyrazole derivatives having cb-1 agonistic activity
KR20060131861A (ko)	2006-12-20	Ｃｂ1-길항 활성을 갖는 1,3,5-삼치환된4,5-디하이드로-1ｈ-피라졸 유도체
PT2069310E (pt)	2012-02-28	Derivados de sulfonilpirazole e sulfonilpirazolina carboxamidina como antagonistas 5-ht6
US20210393644A1 (en)	2021-12-23	4-Pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
CA2632582A1 (en)	2007-06-28	4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
KR102728343B1 (ko)	2024-11-11	이미다조피리딘 유도체 및 이의 약제로서의 용도
CN102112466A (zh)	2011-06-29	具有cb1-拮抗活性的(5r)-1，5-二芳基-4，5-二氢-1h-吡唑-3-甲脒衍生物
RU2354650C2 (ru)	2009-05-10	Тетразамещенные производные имидазола в качестве модуляторов рецепторов cb1 каннабиноидов с высокой селективностью к подтипам рецепторов cb1/cb2
US12398143B2 (en)	2025-08-26	Imidazopyrazine derivatives and the use thereof as medicament
CN101848907A (zh)	2010-09-29	具有大麻素-cb1拮抗作用和乙酰胆碱酯酶抑制作用的组合的化合物
TWI296618B (en)	2008-05-11	Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
HK1117512A (en)	2009-01-16	4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
AU2008263915A1 (en)	2008-12-18	4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
UA82908C2 (en)	2008-05-26	1h-imidazole derivatives as cannabinoid receptor modulators
CZ176895A3 (cs)	1996-02-14	Substituované N-oxidované deriváty l-(7-chlorchinolein-4-yl)-pyrazoI-3-karboxamidů, způsob jejich přípravy a farmaceutické přípravky sjejich obsahem